帕博利珠单抗用于不适合顺铂治疗的晚期、不可切除或转移性尿路上皮癌患者的成本效益分析
本研究基于KEYNOTE-052数据拟合生存曲线,在瑞典医疗体系下评估帕博利珠单抗一线治疗PD-L1强阳性、不适合顺铂的晚期尿路上皮癌患者的成本效益。结果显示,与卡铂联合吉西他滨相比,帕博利珠单抗可提高生存2.11年、增加1.71个质量调整生命年(QALY),增量成本效益比(ICER)为53055欧元/QALY;与吉西他滨单药相比,提高生存2.16年、增加1.75个QALY,ICER为54415欧元/QALY。在100000欧元/QALY的支付意愿阈值下,帕博利珠单抗具有成本效益。
要点
- 帕博利珠单抗对比卡铂联合吉西他滨:生存提高2.11年,QALY增加1.71,ICER为53055欧元/QALY。
- 帕博利珠单抗对比吉西他滨单药:生存提高2.16年,QALY增加1.75,ICER为54415欧元/QALY。
- 在100000欧元/QALY的支付意愿阈值下,帕博利珠单抗对比两种方案均具有成本效益。
核心结论
- 在100000欧元/QALY的支付意愿阈值下,帕博利珠单抗对比卡铂联合吉西他滨和吉西他滨单药均具有成本效益。
研究设计与样本
- 基于KEYNOTE-052的生存数据拟合参数生存曲线外推临床结局,采用模拟治疗比较和网络Meta分析估计帕博利珠单抗对比卡铂联合吉西他滨及吉西他滨单药的相对疗效。
- 利用KEYNOTE-052的EQ-5D数据估计效用值,资源使用和成本输入基于瑞典地区定价目录和临床医生意见。
- 分析对象为瑞典PD-L1强阳性、不适合顺铂治疗的晚期或转移性尿路上皮癌患者。
主要发现
- 帕博利珠单抗对比卡铂联合吉西他滨:生存提高2.11年,QALY增加1.71,成本增加90520欧元,ICER为53055欧元/QALY。
- 帕博利珠单抗对比吉西他滨单药:生存提高2.16年,QALY增加1.75,成本增加95055欧元,ICER为54415欧元/QALY。
- 结果通过确定性敏感性和概率敏感性分析进行检验。
关键数值与推荐
- 成本效益判定阈值为100000欧元/QALY。
- 帕博利珠单抗对比卡铂联合吉西他滨的ICER为53055欧元/QALY。
- 帕博利珠单抗对比吉西他滨单药的ICER为54415欧元/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet need for effective therapies for patients with advanced or metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatin-ineligible patients experience a high frequency of adverse events from the most commonly used standard of care treatment, carboplatin plus gemcitabine, or alternative treatment with gemcitabine monotherapy. Pembrolizumab is a potent, highly selective humanised monoclonal antibody that releases checkpoint inhibition of the immune response system, and provides a new alternative for these patients. OBJECTIVE: To assess the cost-effectiveness of pembrolizumab for first-line treatment of urothelial carcinoma ineligible for cisplatin-based therapy in patients with strongly PD-L1-positive tumours in Sweden. DESIGN, SETTING, AND PARTICIPANTS: Parametric survival curves were fitted to overall survival, progression-free survival, and time on treatment data from KEYNOTE-052 to extrapolate clinical outcomes. A simulated treatment comparison and a network meta-analysis were conducted to estimate the comparative efficacy of pembrolizumab versus carboplatin plus gemcitabine and gemcitabine monotherapy. EQ-5D data from KEYNOTE-052 were used to estimate utility, while resource use and cost inputs were estimated using Swedish regional pricing lists and clinician opinion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The model reported costs, life years, and quality-adjusted life years (QALYs), and results were tested using deterministic and probabilistic sensitivity analysis. RESULTS AND LIMITATIONS: We estimated that pembrolizumab would improve survival by 2.11 and 2.16 years and increase QALYs by 1.71 and 1.75 compared to carboplatin plus gemcitabine and gemcitabine monotherapy, respectively. Pembrolizumab was associated with a cost increase of €90520 versus carboplatin plus gemcitabine and €95055 versus gemcitabine, with corresponding incremental cost-effectiveness ratios of €53055/QALY and €54415/QALY. CONCLUSIONS: At a willingness-to-pay threshold of €100000/QALY, pembrolizumab is a cost-effective treatment versus carboplatin plus gemcitabine and versus gemcitabine. PATIENT SUMMARY: This is the first analysis to show that pembrolizumab is a cost-effective option for first-line treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma in Sweden.
引用
- Patterson K, Prabhu V, Xu R, et al. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. Eur Urol Oncol. 2018. PMID: 31412011. doi:10.1016/j.euo.2018.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。